| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/25/2005 | US20050186223 Virus production |
| 08/25/2005 | US20050186222 Vaccines against West Nile Virus |
| 08/25/2005 | US20050186220 derived from canine distemper virus; vaccines for inducing immune response |
| 08/25/2005 | US20050186219 Transgenic plant-based vaccines |
| 08/25/2005 | US20050186217 Compositions produced using enteric pathogens and methods of use |
| 08/25/2005 | US20050186215 CUDR as biomarker for cancer progression and therapeutic response |
| 08/25/2005 | US20050186214 Antiproliferative agents; chimeric molecules to direct cytotoxins, imaging reagents, and drugs; cells, kits |
| 08/25/2005 | US20050186213 Anti-PECAM therapy for metastasis suppression |
| 08/25/2005 | US20050186212 Trefoil factor 3 (TFF3) as a target for anti-cancer therapy |
| 08/25/2005 | US20050186209 Protein between 30% but less than 100% identical to a human protein, contains a mutation characteristic of an analogous non-human protein; is capable of raising antibodies in human, antibodies bind to both the human protein and the polypeptide |
| 08/25/2005 | US20050186208 Anti-neoplastic composition of adrenocorticosteroides, progestins, estrogens, antiestrogen, androgens; breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, pancreatic cancer, soft-tissue sarcoma |
| 08/25/2005 | US20050186207 Regulatory T cells suppress autoimmunity |
| 08/25/2005 | US20050186206 Administering a CD20 antagonist antibody; autoimmune disease |
| 08/25/2005 | US20050186205 Administering unlabelled anti-CD20 antibody that binds to the CD20 antigen present on lymphoma cells; a second treatment of cyclophosphamide, doxorubicin, vincristine or prednisone |
| 08/25/2005 | US20050186204 Antagonists of placental growth factor receptor and signaling; preventing bone loss and/or enhancing bone healing |
| 08/25/2005 | US20050186203 Isolated antibody bound to human insulin-like growth factor-I receptor, identification of its CDRs (complementarity-determining regions), inhibiting the tyrosine kinase activity of the IGF-IR receptor |
| 08/25/2005 | US20050186199 An antibody directed against particular amino acid regions of Hsp70B' and its preparation by administering a peptide corresponding, or antigenically equivalent, to those regions; detection of the stress-inducible Hsp70B' protein |
| 08/25/2005 | US20050186192 Administering the vaccine having attenuated T cells reactive against epitopes of myelin basic protein |
| 08/25/2005 | US20050186187 Altering the expression levels of a protein; modulating the activity of secretory leukocyte protease inhibitor (SLPI), CD53, or Transferrin-1 in a cell and culturing the cells |
| 08/25/2005 | US20050186186 Tumor cell having DcR3/TR6, a new member of the TNFR family, anchored at its surface |
| 08/25/2005 | US20050186180 Recombinant virus encoding an antigen of a disease state; second recombinant virus encoding an immunostimulatory molecule with an exogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviral drug or antifungal drug. |
| 08/25/2005 | US20050186146 Interleukin-13 antagonist powders, spray-dried particles, and methods |
| 08/25/2005 | US20050186136 Soluble JAM-1, 2, and 3 as diagnostic & prognostic markers in cardiovascular, vascular, and inflammatory disorders |
| 08/25/2005 | CA2563904A1 Isolated plasma and method for hyperimmunisation and plasma collection |
| 08/25/2005 | CA2561531A1 Inhibition of factor b, the alternative complement pathway and methods related thereto |
| 08/25/2005 | CA2559889A1 Targeted atherosclerosis treatment |
| 08/25/2005 | CA2559359A1 Identification of snps associated with hyperlipidemia, dyslipidemia and defective carbohydrate metabolism |
| 08/25/2005 | CA2556739A1 Pharmaceutical composition for treatment of immunological disorders |
| 08/25/2005 | CA2556245A1 Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| 08/25/2005 | CA2556095A1 Live attenuated salmonella for use as vaccine |
| 08/25/2005 | CA2555848A1 Antibody targeting osteoclast-associated protein |
| 08/25/2005 | CA2555791A1 Highly concentrated liquid formulations of anti-egfr antibodies |
| 08/25/2005 | CA2555789A1 Ctgf as target for the therapy of diabetic nephropathy |
| 08/25/2005 | CA2555699A1 Monoclonal antibody based biomarker discovery and development platform |
| 08/25/2005 | CA2555666A1 Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| 08/25/2005 | CA2555503A1 Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto |
| 08/25/2005 | CA2555393A1 Hybrid proteins of active-site serine beta-lactamase |
| 08/25/2005 | CA2555365A1 Methods and compositions for treating tumors and metastatic disease |
| 08/25/2005 | CA2555319A1 Inhibiting cav3 isoforms and the .delta.25b splice variants for the diagnosis and treatment of cancer |
| 08/25/2005 | CA2555274A1 Chimeric vegf peptides |
| 08/25/2005 | CA2555253A1 Compositions of pamps and listeria monocytogenes and methods of use |
| 08/25/2005 | CA2555145A1 Diagnosis and therapeutics for cancer |
| 08/25/2005 | CA2555144A1 Methods of treating skin disorders |
| 08/25/2005 | CA2555142A1 Cell proliferation associated with ccx ckr expression |
| 08/25/2005 | CA2554978A1 Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity |
| 08/25/2005 | CA2554971A1 Methods of diagnosing and treating pre-eclampsia or eclampsia |
| 08/25/2005 | CA2554664A1 Complexed polypeptide and adjuvant for improved vaccines |
| 08/25/2005 | CA2554370A1 Compositions and methods of use of w-peptides |
| 08/25/2005 | CA2554337A1 Methods and compositions for dosing of allergens |
| 08/25/2005 | CA2553703A1 Ornithobacterium rhinotracheale subunit vaccines |
| 08/25/2005 | CA2549432A1 Lipid rafts and clostridial toxins |
| 08/24/2005 | EP1566636A1 Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
| 08/24/2005 | EP1566387A2 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 08/24/2005 | EP1565583A2 Hiv vaccine formulations |
| 08/24/2005 | EP1565581A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 08/24/2005 | EP1565493A2 Antibody for the thyrotropin receptor and uses thereof |
| 08/24/2005 | EP1565489A2 Novel raag10 cell surface target and a family of antibodies recognizing that target |
| 08/24/2005 | EP1565482A2 A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
| 08/24/2005 | EP1565478A2 Polysaccharide vaccine for staphylococcal infections |
| 08/24/2005 | EP1565214A2 Treatment of immunological renal disorders by lymphotoxin pathway inhibitors |
| 08/24/2005 | EP1565212A1 Gastrin compositions and formulations, and methods of use and preparation |
| 08/24/2005 | EP1565211A2 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles |
| 08/24/2005 | EP1565210A2 Treatment of mammalian reaction to ige interactions |
| 08/24/2005 | EP1565080A2 Novel immunogenic proteins of leptospira |
| 08/24/2005 | EP0792370B1 Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4 |
| 08/24/2005 | EP0684955B1 Nuclear matrix proteins |
| 08/24/2005 | EP0681483B1 Compositions and methods for delivery of genetic material |
| 08/24/2005 | EP0662132B1 Self-assembling recombinant hpv16 papillomavirus capsid proteins |
| 08/24/2005 | CN1659438A G-protein coupled receptor ligands and methods |
| 08/24/2005 | CN1659436A Method for isolating ligands |
| 08/24/2005 | CN1659187A Ferritin fusion proteins for use in vaccines and other applications |
| 08/24/2005 | CN1658924A Method of treating biological materials with translating electrical fields and electrode polarity reversal |
| 08/24/2005 | CN1658906A Mycoplasma polypeptides |
| 08/24/2005 | CN1658904A Combinations comprising epothilones and pharmaceutical uses thereof |
| 08/24/2005 | CN1658901A Methods for treating TWEAK-related conditions |
| 08/24/2005 | CN1658900A Allergy vaccine composition, production method thereof and use of same in allergy treatment |
| 08/24/2005 | CN1658899A Modified CEA nucleic acid and expression vectors |
| 08/24/2005 | CN1658897A Methods for treating muscle injuries |
| 08/24/2005 | CN1658895A Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 08/24/2005 | CN1658845A Stealth lipid nanocapsules, methods for the preparation thereof, and use thereof as a carrier for active principle(s) |
| 08/24/2005 | CN1658806A Method and tools for oral hygiene |
| 08/24/2005 | CN1658767A Composition for modulating a physiological reaction or inducing an immune response |
| 08/24/2005 | CN1657625A Nucleolide specific for O-antigenic of escherichia coli o131 type |
| 08/24/2005 | CN1657541A Process for preparating specificity complex IgY of anti coxsackie virus myocarditis and its compound preparation |
| 08/24/2005 | CN1216075C Hepatitis C virus high change region 1 synthetic peptide and its use |
| 08/24/2005 | CN1215879C 人类sars冠状病毒受体抑制剂 Human sars coronavirus receptor inhibitors |
| 08/24/2005 | CN1215878C Composite hepatitis B vaccine for treatment and its preparation method |
| 08/23/2005 | US6933377 Compositions comprising multiple immunodeficiency virus subunits for inducing an immune response |
| 08/23/2005 | US6933286 Therapeutic delivery compositions and methods of use thereof |
| 08/23/2005 | US6933285 Flavin N-oxides: new anti-cancer agents and pathogen eradication agents |
| 08/23/2005 | US6933271 Aimed at neoplastic cells with gonadotropin releasing hormone binding sites; anticarcinogenic agents; genetically engineered Pseudomonas Exotoxin |
| 08/23/2005 | US6933148 Cell separation compositions and methods |
| 08/23/2005 | US6933130 Recombinants process for preparing a complete malaria antigen, gp190/MSP1 |
| 08/23/2005 | US6933108 Treating viral disease in mammals; administer viricide to mammal, monitor activity of virus, reduced viral activity indicates effective viricide |
| 08/23/2005 | US6932987 A chemical formulation which enhances metabolism, is formed into tablets, each of such tablets containing L-carnitine; conjugated linoleic acid, Citrus aurantium; ginger extract, green tea extract,and capsaicin |
| 08/23/2005 | US6932972 Combined vaccine compositions |
| 08/23/2005 | US6932971 Nicotine-hapten composition for diagnosing, preventing and treating drug addiction; vaccine for treating nicotine addiction, palliating nicotine withdrawal, facilitating smoking cessation and/or preventing relapse |
| 08/23/2005 | US6932969 Ig fractions having immunomodulatory activity |
| 08/23/2005 | US6932967 Human medical treatment by aerosol inhalation of immunoglobulin A |
| 08/23/2005 | CA2186044C Novel mutated viruses, anti-viral compounds and novel methods of making vaccines |